News

ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.

Three-year agreement will support research on treatments for major brain disorders in Neuroscience Catalyst project.

Natoli Engineering Company partnered with the Brooklyn campus of Long Island University to open the Natoli Institute for Industrial Pharmacy Research and Development.Natoli Engineering Company announced the opening of the Natoli Institute for Industrial Pharmacy Research and Development. The institute was opened in partnership with the Arnold and Marie Schwartz College of Pharmacy and Health Sciences on the Brooklyn campus of Long Island University and features suites for dispensing, formulation, compression, and coating.

The new China facility will be Merck KGaA's biopharmaceuticals division's second largest worldwide.

The companies plan to develop and commercialize duvelisib (IPI-145).

PDA surveys are designed to evaluate quality metrics practices at member organizations.

Travtec, a packaging line solutions specialist, has opened a second facility close to its Leigh, Lancashire headquarters. This move is part of an investment to expand the company?s operations to meet continuing demand for its systems, particularly as the pharmaceutical industry prepares for the current and forthcoming track and trace legislation, including the 2017 European Falsified Medicines Directive.

DPT Laboratories acquired Media Pharmaceuticals' Lakewood, New Jersey facilities, providing space for aseptic processing suites and filling equipment.

KEYTRUDA was approved for the treatment of unresectable or metastatic melanoma and disease progression.

AbbVie and Calico announce a novel collaboration to accelerate the discovery, development, and commercialization of new therapies.

FDA gives NewLink Genetics approval to proceed to Phase 1 clinical studies of Ebola vaccine.

Catalent's addition of an automated prefilled syringe clinical packaging line at its Philadelphia facility will support its work with Eli Lilly.

Meggle Group Wasserburg has been granted an EXCiPACT certificate.

Conventional tablets may no longer be the go-to solution.

The National Institute of Allergy and Infectious Diseases will begin the first in a series of trials for an Ebola vaccine during the week of Sept. 1.

ISPE released an advance look at the Introductory Summary of its Drug Shortages Prevention Plan.

FDA found violations of cGMP at finished-drug manufacturer in India.

Concerns about quality in overseas production may bring generic drug production back to the United States, concludes CPhI study.

Consumers warned about products claiming to prevent or treat the Ebola virus.

Cubist Pharmaceuticals voluntarily recalls certain lots of CUBICIN 500 mg in 10 mL single-use vials because of the presence of particulate matter.

The European system for assessing drugs will be used as a model internationally.

PharmaChk, a portable device being developed to detect substandard medicines, receives $2-million grant.

Allied-Bristol Life Sciences will focus on converting university research into therapeutic candidates.

GlobalData's report looks at the growth of monoclonal antibodies in the market for acute coronary syndrome treatment.

ChargePoint Technology announced that it has acquired the assets of Forac Limited.

BioSpectra's Pennsylvania facility will manufacture biological buffers, pharmaceutical excipients, and laboratory reagents.

Metrics Contract Services adopts a more descriptive name and brand that identifies it as being part of the Mayne Pharma global family.

Acquisition of Almirall?s products will provide boost to revenue and strengthen AstraZeneca?s respiratory product line.

EMA has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

Catalent?s $870 million IPO will help company reduce debt, enable future growth.